"Biphenyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings.
| Descriptor ID |
D001713
|
| MeSH Number(s) |
D02.455.426.559.389.185
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biphenyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Biphenyl Compounds".
This graph shows the total number of publications written about "Biphenyl Compounds" by people in this website by year, and whether "Biphenyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.
-
Kim DH, Chien FJ, Eisen HJ. Pharmacologic Management for Heart Failure and Emerging Therapies. Curr Cardiol Rep. 2017 08 24; 19(10):94.
-
Patsenker E, Chicca A, Petrucci V, Moghadamrad S, de Gottardi A, Hampe J, Gertsch J, Semmo N, Stickel F. 4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice. J Mol Med (Berl). 2017 10; 95(10):1077-1089.
-
Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget. 2016 Jul 26; 7(30):48280-48295.
-
Feldman AM, Haller JA, DeKosky ST. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. JAMA. 2016 Jan 05; 315(1):25-6.
-
Schultz TC, Valenzano JP, Verzella JL, Umland EM. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis. Womens Health (Lond). 2015 Nov; 11(6):805-14.
-
Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun; 59(6):539-46.
-
Tveit A, Bollmann A, Seljeflot I, Husser D, Stridh M, S?rnmo L, Arnesen H, Olsson SB, Smith P. Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation. Thromb Haemost. 2009 Mar; 101(3):601-3.
-
Bollmann A, Tveit A, Husser D, Stridh M, S?rnmo L, Smith P, Olsson SB. Fibrillatory rate response to candesartan in persistent atrial fibrillation. Europace. 2008 Oct; 10(10):1138-44.